2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2839

Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
Abstract Number: 2840

Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Abstract Number: 2841

Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Abstract Number: 2842

Tumor Necrosis Factor Alpha Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome
Abstract Number: 2843

Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)
Abstract Number: 2844

Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies
Abstract Number: 2845

A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Ankylosing Spondylitis
Abstract Number: 2846

Modifications to Biologic Therapy and Economic Implications in Psoriatic Arthritis Patients
Abstract Number: 2847

Predictors of Therapeutic Response in Ankylosing Spondylitis Patients Initiating Therapy with Adalimumab in a German Non-Interventional Study
Abstract Number: 2848

Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Abstract Number: 2849

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Abstract Number: 2850

Etanercept Treatment in Psoriatic Arthritis: Need for Co-Medication?
Abstract Number: 2851

Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry
Abstract Number: 2853

Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial
Abstract Number: 2854

Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].